Can fite Biopharma Ltd (CANF) - News Archive

In a significant move to bolster its financial resources, Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a leading biotechnology entity specialising in pioneering small-molecule drugs for the treatment of o...

In a significant move that could reshape the landscape of rare disease treatment, Can-Fite Biopharma Ltd. has announced plans to initiate a Phase II clinical trial aimed at addressing Lowe Syndrome, a rare genetic disor...

In a significant advancement for pancreatic cancer treatment, Can-Fite BioPharma Ltd. has announced that its investigational oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. Foo...

Can-Fite Biopharma: Turning a Loss into a $325 Million Opportunity with Veterinary Licensing AgreementIn the ever-evolving landscape of biotechnology, few stories emerge with the potential to reshape a company s fortune...

Can-Fite BioPharma Secures $5 Million Through Warrant Exercise: A Strategic Move for Oncology and Inflammatory Disease Drug Development RAMAT GAN, Israel August 8, 2024 Can-Fite BioPharma Ltd., a growing player in the b...

During the current month, the shares of Can Fite Biopharma Ltd have been showing promising performance compared to the overall market. With a performance of 0.55%, the biopharmaceutical company seems to be on the move a...

Can-Fite BioPharmaLtd., a leading biotechnology company specializing in the development of novel small molecule drugs for oncological and inflammatory diseases, is pleased to invite investors to an exclusive live webina...

Can-Fite BioPharma Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerIn a recent press release, Can-Fite BioPharma announced that it has submitted an application to the U.S. Fo...